Milestone's Etripamil Nasal Spray Revolutionizes PSVT Treatment With Home-Based Therapy

Milestone Pharmaceuticals has launched a breakthrough approach to managing paroxysmal supraventricular tachycardia with the FDA approval of CARDAMYST, fundamentally reshaping how patients handle psvt episodes. The product represents the first self-administered treatment option for this common cardiac condition, marking a watershed moment in cardiac care delivery.

Understanding PSVT and the Need for Innovation

Paroxysmal supraventricular tachycardia affects more than two million Americans, causing sudden episodes of rapid heart rate that typically range from 160 to 220 beats per minute. Patients experiencing psvt episodes describe intense palpitations, excessive sweating, chest pressure, shortness of breath, and overwhelming anxiety. These episodes can strike suddenly and unpredictably, particularly among younger adults during or after vigorous physical exertion. The condition’s impact extends beyond physical symptoms, often forcing patients to seek emergency care during acute episodes.

For decades, psvt management relied exclusively on intravenous adenosine administered in hospital or emergency department settings, requiring patients to seek immediate medical intervention whenever symptoms emerged. This approach limited patient autonomy and created significant healthcare burden.

How CARDAMYST Changes PSVT Management

CARDAMYST (etripamil) represents the first FDA-approved treatment for psvt in over 30 years, offering a fundamentally different approach. As a rapid-acting calcium channel blocker delivered via nasal spray, it enables patients to self-administer therapy during acute episodes outside clinical settings. This innovation allows individuals experiencing psvt to regain control over their condition, treating episodes at home or anywhere symptoms arise rather than waiting for emergency services.

The product launched through U.S. retail pharmacies with a patient assistance program designed to enhance accessibility. Milestone structured copays at a $25 maximum for eligible commercially insured patients, alongside reimbursement support and benefit verification services to ease the financial burden.

Market Significance and Industry Impact

This launch signals Milestone Pharmaceuticals’ transformation from a clinical-stage organization into a commercial entity with a marketed product addressing a significant patient population. The shift from intravenous acute-care delivery to self-administered home therapy represents a paradigm change in how psvt patients experience their condition, potentially improving quality of life and reducing emergency department utilization.

Stock performance reflects market positioning, with MIST trading at $1.93 (down 2.51%) following recent activity and having ranged between $0.62 and $3.06 over the past year as the company advanced through commercialization milestones.